Ad blocker interference detected!
Wikia is a free-to-use site that makes money from advertising. We have a modified experience for viewers using ad blockers
Wikia is not accessible if you’ve made further modifications. Remove the custom ad blocker rule(s) and the page will load as expected.
Individual differences |
Methods | Statistics | Clinical | Educational | Industrial | Professional items | World psychology |
Biological: Behavioural genetics · Evolutionary psychology · Neuroanatomy · Neurochemistry · Neuroendocrinology · Neuroscience · Psychoneuroimmunology · Physiological Psychology · Psychopharmacology (Index, Outline)
|Systematic name|| 1-Amino-13-ethylidene-11-methyl-|
|Molar mass||242.32 g/mol|
|Density and phase||? g/cm3, ?|
|Solubility in water||? g/100 ml (? °C)|
|Melting point||217-219 °C (? K)|
|Boiling point||? °C (? K)|
|Chiral rotation [α]D||-147° (c = 0.36, MeOH)|
|Flash point||? °C|
|R/S statement|| R: ? |
| Except where noted otherwise, data are given for|
materials in their standard state (at 25 °C, 100 kPa)
Infobox disclaimer and references
Huperzine A, is a naturally occurring sesquiterpene alkaloid found in the extracts of the firmoss Huperzia serrata. The extract has been used in China for centuries for the treatment of swelling, fever and blood disorders. Recently in clinical trials in China, it has demonstrated neuroprotective effects. It is currently being investigated as a possible treatment for diseases characterized by neurodegeneration – particularly Alzheimer’s disease.
Huperzine A has attracted the attention of Western medical science. It has been found to be an inhibitor of the enzyme acetylcholinesterase. This is the same mechanism of action of pharmaceutical drugs such as galantamine and donepezil used to treat Alzheimer's disease. <p>Clinical trials in China have shown that huperzine A is comparably effective to the drugs currently on the market, and may even be a bit safer in terms of side effects. Currently, the National Institute on Aging is conducting a Phase II clinical trial to evaluate the safety and efficacy of huperzine A in the treatment of Alzheimer's disease in a randomized controlled trial of its effect on cognitive function.
- Zangara, A. The psychopharmacology of huperzine A: an alkaloid with cognitive enhancing and neuroprotective properties of interest in the treatment of Alzheimer's disease. Pharmacol Biochem Behav. 2003 Jun;75(3):675-86.
- Bai, D. L.; Tang, X. C.; He, X. C. Huperzine A, a potential therapeutic agent for treatment of Alzheimer's disease. Current Medicinal Chemistry , 2000, vol. 7, iss. 3, p. 355-374.
- Tang, X. C.; He, X. C.; Bai, D. L. Huperzine A: a novel acetylcholinesterase inhibitor. Drugs of the Future, 1999, vol. 24, iss 6, p. 647-663.
- Kozikowski, Alan P.; Tueckmantel, Werner. Chemistry, Pharmacology, and Clinical Efficacy of the Chinese Nootropic Agent Huperzine A. Accounts of Chemical Research, 1999, vol 32, iss 8, p. 641-650.
|This page uses Creative Commons Licensed content from Wikipedia (view authors).|